TRH attenuates scopolamine-induced memory impairment in humans

@article{Molchan1990TRHAS,
  title={TRH attenuates scopolamine-induced memory impairment in humans},
  author={Susan E. Molchan and Alan M. Mellow and Brian A Lawlor and Herbert J. Weingartner and Robert M. Cohen and Martin R. Cohen and Trey P Sunderland},
  journal={Psychopharmacology},
  year={1990},
  volume={100},
  pages={84-89}
}
The brain tripeptide thyrotropin-releasing hormone (TRH) has been demonstrated to facilitate cholinergic neurotransmission. To test its interaction with the cholinergic system in humans, high-dose TRH (0.5 mg/kg) or placebo was administered intravenously (IV) to normal controls pretreated with scopolamine (0.5–0.75 mg IV), a centrally active muscarinic antagonist, which has been used to model aspects of the memory impairment of normal aging and of dementia. Compared to placebo, TRH markedly… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

The scopolamine model as a pharmacodynamic marker in early drug development

VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Pharmacology of thyrotropin-releasing hormone.

  • Annual review of pharmacology and toxicology
  • 1986
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs.

  • The Journal of pharmacology and experimental therapeutics
  • 1975
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…